NCT04284514View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

December 15, 2019

Study Completion Date

December 15, 2019

Conditions
Ocular HypertensionPrimary Open Angle Glaucoma
Interventions
DRUG

AKB-9778 Ophthalmic Solution

AKB-9778 Ophthalmic Solution

DRUG

Placebo Ophthalmic Solution

Matched vehicle-control

Trial Locations (2)

75247

Covance Clinical Research Unit, Dallas

78744

PPD, Austin

Sponsors
All Listed Sponsors
lead

Aerpio Therapeutics

INDUSTRY

NCT04284514 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution | Biotech Hunter | Biotech Hunter